Skip to content
Search

Latest Stories

MHRA issues advice for safe use of anticoagulants during Covid-19 pandemic

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued an advice for the safe use of anticoagulants during the current Covid-19 pandemic.

The advice includes a reminder for doctors and other healthcare professionals to continue regular blood tests in patients taking warfarin or any other vitamin K antagonist, such as acenocoumarol (Sinthrome) or phenindione (Dindevan) and who have developed an additional illness.


The blood test will indicate if there is a need to change the dose of the anticoagulant.

“In particular, it is important these regular blood tests are done in any patients with symptoms of Covid-19 or who have tested positive so that they can be given the right care at an early stage to reduce the risk of bleeding,” the health regulator has said.

It is import for the GPs to conduct regular blood tests for the patients with Covid-19 symptoms who are being treated with the anticoagulants.

The latest advice also includes a reminder of the potential for drug interactions between some anticoagulant tablets and medicines used to treat infections. This means antibiotics may interact with warfarin or other vitamin K antagonists.

Other anticoagulants tablets including apixaban (Eliquis), dabigatran (Pradaxa), edoxaban (Lixiana) or rivaroxaban (Xarelto) can also interact with certain medicines.

These drug interactions can potentially increase the blood-thinning effect of some anticoagulants and lead to a higher risk of bleeding.

The healthcare professionals can find further information on these interactions in the patient information leaflet which accompanies each pack of medicine.

If a patient is taking warfarin or any other vitamin K antagonist, it is important to be consistent with what he eat and drink because this may affect how well this medicine works.

The patients should not drink large amounts of alcohol while taking warfarin or any other vitamin K antagonist. They are also advised to take the daily dosage at the same time of day swallowed whole with a glass of water.

The patients have been advised to inform their GP if they…

  • have sickness or diarrhoea or have lost their appetite;
  • have started taking any new medicines, including antibiotics, antivirals, over the counter medicines, herbal remedies or vitamin supplements;
  • have recently stopped smoking or are drinking more, or less, alcohol than usual;
  • are taking warfarin or any other vitamin K antagonist and are unable to attend their next scheduled blood test for any reason, including because they feel unwell.

Sarah Branch, Director of Vigilance and Risk Management of Medicines, said: “Patient safety is our main priority and it is important that patients taking blood thinners continue to be monitored carefully as we all coordinate responses to Covid-19.

“We are working closely with other healthcare partners to protect public health in the UK. Please continue to follow NHS Covid-19 advice and communicate with your GP and healthcare team to manage your treatment.”

It is important that the patients follow the directions of their healthcare team and do not suddenly stop taking or alter the dosage of their prescribed medications unless told to do so.

More For You

GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less
Community Pharmacy Scotland secures £10m reimbursement uplift amid ongoing negotiations

Negotiations continue on the Global Sum element of remuneration.

Getty Images

Community Pharmacy Scotland secures £120m reimbursement deal for 2025/26

Community Pharmacy Scotland (CPS) has accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

The agreement marks the first phase of ongoing negotiations surrounding community pharmacy funding for the upcoming financial year.

Keep ReadingShow less